Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

CONCLUSIONS: XR (0.2 and 0.4 mg/day) was non-inferior to IR (0.2 mg/day). XR 0.4 mg/day demonstrated a more potent triglyceride-lowering effect than XR 0.2 mg/day and should be considered for patients with high triglyceride levels.PMID:38616112 | DOI:10.5551/jat.64677

Source: Journal of Atherosclerosis and Thrombosis - April 14, 2024 Category: Cardiology Authors: Hidenori Arai Shizuya Yamashita Eiichi Araki Koutaro Yokote Ryohei Tanigawa Ayumi Saito Sayumi Yamasaki Hideki Suganami Shun Ishibashi Source Type: research